Verana Health, Inc.

Verana Health is a digital health company that leverages real-world data (RWD) and artificial intelligence (AI) to accelerate healthcare innovation and optimize drug and device development. The company's mission is to empower clinical researchers, life science analysts, and clinicians with data-driven insights to advance medical research. Headquartered in San Francisco, California, Verana Health utilizes physician expertise and advanced technology to unlock the potential of RWD. [1, 2, 3, 8, 10, 12, 13, 23, 26]

Verana Health offers a data insights platform, research services, and advanced analytics platforms. Key offerings include "Qdata," which are disease-specific, research-ready data modules, powered by "VeraQ," a population health data engine. The company also provides solutions for clinical trials, such as Site Explorer and Verana Trial Connect, and supports clinicians with quality reporting services like MIPS. Verana Health serves life sciences companies, contract research organizations (CROs), healthcare providers, and specialty medical societies, drawing from an exclusive real-world data network of over 20,000 clinicians and more than 90 million de-identified patients across ophthalmology, urology, neurology, and oncology. [2, 3, 15, 16, 18, 20, 24, 27, 28]

In a significant development, Verana Health merged with COTA, Inc. on January 8, 2026, to expand its oncology offerings and enhance its real-world data capabilities. This merger broadened the company's patient access and client base, now serving 17 of the top 20 global biopharma companies. Sujay Jadhav leads the company as CEO. Verana Health is recognized as a leader in real-world evidence solutions, leveraging AI and machine learning technology, and has secured substantial funding, including a $150 million Series E round in January 2022, contributing to a total funding exceeding $360 million. [1, 3, 7, 9, 11, 15, 16, 17, 18, 19, 21, 23, 25, 26, 28]

Latest updates

Verana Health Bolsters Prostate Cancer Data Offering Through COTA Merger, AQUA Partnership

Event summary

  • Verana Health launched the world’s largest curated real-world dataset for prostate cancer, aggregating data from over 430,000 patients.
  • The dataset leverages data from the American Urological Association (AUA) Quality (AQUA) Registry and is expanded by Verana Health’s recent acquisition of COTA.
  • The COTA merger increased Verana Health’s network access to over 30 Academic Medical Centers and 10 million oncology patients.
  • The dataset includes key variables like Gleason Score, TNM Stage, and PSA levels, critical for assessing prostate cancer aggressiveness and treatment response.

The big picture

Verana Health’s move underscores the growing importance of real-world data (RWD) and real-world evidence (RWE) in accelerating drug development and improving patient care. The acquisition of COTA and partnership with the AUA position Verana Health as a key player in the burgeoning RWD market, which is increasingly vital as clinical trials face challenges in reflecting diverse patient populations and long-term outcomes. This expansion also highlights the trend of data aggregation and AI-driven analytics becoming essential for unlocking value from healthcare data.

What we're watching

Data Integration
The success of Verana Health’s strategy hinges on effectively integrating the COTA data and technology, and whether that integration will yield the promised expansion of data access and analytical capabilities.
Regulatory Scrutiny
Increased reliance on RWD for clinical decision-making will likely draw greater regulatory scrutiny regarding data privacy, security, and the validation of AI/ML algorithms used in data curation.
Commercial Adoption
The pace at which life sciences companies adopt this dataset and incorporate its insights into drug development and clinical trial design will determine Verana Health’s revenue growth and long-term viability.

Verana Health Deploys AI Agent to Navigate Complex MIPS Reporting

Event summary

  • Verana Health released 'Agent Claire,' an AI agent designed to automate and improve compliance with Medicare's MIPS program.
  • Agent Claire is initially available to members of the American Academy of Ophthalmology's IRIS® Registry.
  • The AI agent aims to unify data and provide actionable insights for clinicians to optimize MIPS performance.
  • Verana Health CEO Sujay Jadhav highlighted the shift towards 'systems that think, predict, and act in real time' as a competitive advantage.
  • A webinar, 'From Rescue to Resilience,' will be held on May 14th to discuss the new agent in detail.

The big picture

The release of Agent Claire reflects the growing pressure on healthcare providers to optimize performance under value-based reimbursement models like MIPS. The increasing adoption of AI in healthcare, as highlighted by Deloitte’s survey, signals a broader trend towards automation and data-driven decision-making to manage costs and improve efficiency. Verana Health’s move positions them to capitalize on this trend, but also exposes them to the risks associated with nascent AI technologies in a highly regulated sector.

What we're watching

Expansion Scope
Verana Health’s commitment to extending Agent Claire across its suite of applications suggests a broader monetization strategy beyond ophthalmology, potentially impacting its competitive positioning in other specialties.
Regulatory Risk
The reliance on AI for MIPS compliance introduces regulatory risk, as evolving guidelines and scrutiny of AI in healthcare could necessitate significant adjustments to Agent Claire’s functionality and validation processes.
Adoption Rate
The success of Agent Claire hinges on adoption rates within the ophthalmology community and beyond; slow uptake could limit Verana Health’s ability to demonstrate ROI and justify further investment in AI-driven solutions.
CID: 1682